lifestyle.longislandreport.org

Author: Kenai Therapeutics/BIOCOM

Kenai Therapeutics Appoints Allen Waldrop to Board of Directors

March 12, 2026
Kenai Therapeutics Appoints Blake Arnold, CFA, as Chief Business Officer

February 24, 2026
Kenai Therapeutics Receives $8M Grant from California Institute for Regenerative Medicine (CIRM) to Advance RNDP-001 for Treatment of Idiopathic Parkinson’s Disease

January 5, 2026
Kenai Therapeutics Announces First Patient Dosed in Phase 1 REPLACE™ Clinical Trial of Neuron Replacement Cell Therapy RNDP-001 for Idiopathic Parkinson’s Disease

December 15, 2025